iBio, Inc. Common Stock (IBIO)

anzi ecco qui la news fresca
9:30AM iBio technology embraced by the Government of Brazil (IBIO) 0.49 : Co announces that a report published on June 18, 2013 in the official Journal of the Government of Brazil under the heading, "Brazil Expands Production of Biological Medicines."

"The ministry will invest U.S. $ 170 million in the construction of the first national factory of organic products made from plant cell technology unprecedented in the country, in Ceara."

Operations should start at full steam in 2016. The new Fiocruz center will be installed in the city of Eusebio near Fortaleza (Ceara) and construction starts from 2014
 

Allegati

  • ibio.jpg
    ibio.jpg
    92,8 KB · Visite: 24
....

OK!
 

Allegati

  • ScreenHunter_381 Aug. 07 22.51.jpg
    ScreenHunter_381 Aug. 07 22.51.jpg
    66,8 KB · Visite: 167

Allegati

  • ibio.jpg
    ibio.jpg
    191,1 KB · Visite: 153
0.535

0.0649 12.13% Range: 0.46 - 0.535
Open: 0.50
Vol: 387,545


Seguire.


Bid: 0.525 Ask: 0.535 Size: 1 x 1
 
iBio receives allowance of patent for HPV-related cancer vaccine in China ( IBIO ) : Co announces that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer treatment as the first product target for advancement on the iBioLaunch platform under the License and Collaboration Agreement between the company and Caliber dated February 14, 2013.

Under the terms of the agreement between iBio and Caliber, iBio will receive license and milestone fees for development of product targets. Caliber is responsible for funding clinical development and commercialization of such collaboration products, and iBio is entitled to receive royalties on such product sales and other revenues. Detailed financial terms of the agreement have not been disclosed.


non ha finito il run.......Imho
 
..
 

Allegati

  • IBIOc1dl0829.png
    IBIOc1dl0829.png
    27,4 KB · Visite: 185
theshareprice30 • 5 minutes ago Flag0
Reply iBio Receives Patent Allowances for Pandemic Influenza Therapeutics.NEWARK, DE--(Marketwired - Mar 27, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza.

------------------------------------------------------------
0.6291
0.1091 17.34% Range: 0.00 - 0.00

http://finance.yahoo.com/news/ibio-receives-patent-allowances-pandemic-123100800.html
 
ma che bel titolo
 

Allegati

  • ibio.png
    ibio.png
    20,9 KB · Visite: 165
Indietro